(MeSH terms): anticoagulants
Factor VIIa and Factor IXa Inhibitors as Anticoagulants: A Review
... As anticoagulants are used as preventive agents to pre- vent blood ...novel anticoagulants, due to their tactical presence at the junction of both extrinsic and intrinsic ...
8
Patient values and preferences when choosing anticoagulants
... The questionnaire started by asking subjects to self-report AF status and use of anticoagulation. Then, we gave subjects a hypothetical scenario describing the risks of having AF, and the advantages and disadvantages of ...
6
Evaluation of Anticoagulants for Serologic Assays of Cholera Vaccination
... This work was supported by grants from the National Research Founda- tion of Korea funded by the Ministry of Education, Science, and Technol- ogy (2010-0029116, 2008-0062421, and 2013K1A2A1058643) and the FIG 3 Titers of ...
5
Approach to the new oral anticoagulants in family practice
... • The new oral anticoagulants (NOACs) are being encountered increasingly in primary care. Although large randomized trials have addressed their efficacy and safety for stroke prevention in atrial fibrillation and ...
7
New anticoagulants for the prevention and treatment of venous thromboembolism
... Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially fatal disease with an annual incidence of 0.1% in Caucasian populations (White 2003). ...
13
Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence
... Background: The use of direct oral anticoagulants (DOACs) is restricted by the limitations of clinical trials guiding therapy for patients with renal impairment, as many of these trial[r] ...
8
Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
... The analyses of the cost side in health economic analyses using a budget impact model approach have shown the importance of analyzing costs from a broader cost perspec- tive than just a focus on drug prices. For optimal ...
11
Satisfaction with oral anticoagulants in patients with atrial fibrillation
... (51.41 ± 8.54 vs 49.53 ± 9.50; P= 0.04). In addition, in those patients with a moderate bleeding risk, burdens with oral anticoagulation were lower. Among patients taking VKA, those subjects with a lower number of INR ...
8
Novel antidotes for target specific oral anticoagulants
... Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings ...
5
Management of bleeding in patients treated with direct oral anticoagulants
... using anticoagulants in combination with as- pirin and/or clopidogrel ...conventional anticoagulants (see above), the effect of combined treat- ment with these agents and aspirin or NSAIDs may be even ...
6
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
... parenteral anticoagulants to their clinical profile is not ...Parenteral anticoagulants have different FDA-approved indications for VTE, and there are differ- ences in the supporting clinical ...
10
DABIGATRAN ETEXILATE: NEW DIRECT THROMBIN INHIBITORS ANTICOAGULANTS
... Appropriate precautions required because as with all anticoagulants, dabigatran etexilate should be used with caution in circumstances associated with an increased risk of bleeding. Bleeding can occur at any site ...
6
New oral anticoagulants: are coagulation units still required?
... Chronic antithrombotic therapy involves the use of anticoagulants, antiplatelets that are given either as monotherapy or in combination for the prevention of thrombotic complications. The well-established benefits ...
6
Outcome of intracerebral hemorrhage associated with different oral anticoagulants
... Prespecified analyses. For the primary prespecified outcome analysis, we fitted a Cox proportional hazards model, adjusting for variables known to affect outcome (age, sex, baseline Glasgow Coma Scale [GCS] score, log ...
11
Perioperative management of patients on direct oral anticoagulants
... oral anticoagulants (DOACs) have been licensed worldwide for several years for various ...oral anticoagulants will undergo an invasive procedure and expert groups have issued several guidelines on ...
17
New anticoagulants for the prevention of venous thromboembolism
... Several new anticoagulant drugs are currently in clinical development for the prophylaxis of VTE. New agents have the potential to make anticoagulant treatment and prophy- laxis easier as they are mostly available for ...
12
The Genetic Basis of Resistance to Anticoagulants in Rodents
... of anticoagulants. and suppression of the VKOR by anticoagulants inhibits During the same time period, coumarin derivatives carboxylation of clotting factors and thus compromises have gained a leading role ...
10
Direct oral anticoagulants and venous thromboembolism
... oral anticoagulants for the treatment and prevention of ...oral anticoagulants ” , “ direct oral anticoagulants”, “apixaban”, “dabigatran”, “edoxaban”, “rivaroxaban”, “venous thromboembolism”, “ deep ...
8
Reversal of direct oral anticoagulants
... 6. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence- based ...
6
Comparison of Oral Anticoagulants
... oral anticoagulants has health care professionals questioning how to choose among ...newest anticoagulants are dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban ...
10